Impact of Lixisenatide (LIXI) Dose Range on Clinical Outcomes with Fixed-Ratio Combination (FRC) iGlarLixi in Patients With T2D

被引：0
|
作者：
Frias, Juan
Hurst, William
Newton, John
Lorenz, Martin
Roberts, Michelle
Dex, Terry
Schmider, Wolfgang
Skolnik, Neil
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1100-P
引用
收藏
页码：A291 / A292
页数：2
相关论文
共 50 条
  • [1] Impact of lixisenatide (LIXI) dose range on glycaemic outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes
    Roberts, M.
    Hurst, W.
    Newton, J.
    Lorenz, M.
    Dex, T.
    Schmider, W.
    Skolnik, N.
    Frias, J.
    DIABETOLOGIA, 2017, 60 : S367 - S368
  • [2] Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes
    Frias, Juan Pablo
    Lorenz, Martin
    Roberts, Michelle
    Dex, Terry
    Schmider, Wolfgang
    Hurst, William
    Skolnik, Neil
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (04) : 689 - 695
  • [3] Impact of Dose Capping in Insulin Glargine/Lixisenatide Fixed-Ratio Combination Trials in Patients with T2D
    Schmider, Wolfgang
    Belder, Rene
    Lee, Michelle
    Meng, Zhaoling
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Wu, Yujun
    Mandema, Jaap
    Newton, John
    Meneghini, Luigi
    Frias, Juan
    DIABETES, 2017, 66 : A292 - A292
  • [4] Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes (vol 35, pg 689, 2019)
    Frias, J. P.
    Lorenz, M.
    Roberts, M.
    Dex, T.
    Schmider, W.
    Hurst, W.
    Skolnik, N.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (04) : 731 - 731
  • [5] Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed-Ratio Combination in Elderly Patients with T2D
    Handelsman, Yehuda
    Chovanes, Christina
    Dex, Terry
    Giorgino, Francesco
    Skolnik, Neil
    Souhami, Elisabeth
    Stager, William
    Frias, Juan Pablo
    DIABETES, 2016, 65 : A246 - A246
  • [6] Insulin Glargine/Lixisenatide Fixed-Ratio Combination Outcomes Are Similar for North American and Rest of World T2D Populations
    Dailey, George
    Bailey, Timothy S.
    Bajaj, Harpreet S.
    Dex, Terry
    Groleau, Melanie
    Stager, William
    Vinik, Aaron
    DIABETES, 2016, 65 : A277 - A277
  • [7] Characteristics and Glycemic Outcomes of T2D Patients (Pts) Titrated to 60 U/day with Insulin Glargine/Lixisenatide Fixed-Ratio Combination (iGlarLixi) vs. Insulin in the LixiLan-L Trial
    Blonde, Lawrence
    Bailey, Timothy S.
    Chao, Jason
    Dex, Terry
    Frias, Juan P.
    Meneghini, Luigi F.
    Roberts, Michelle
    Aroda, Vanita R.
    DIABETES, 2017, 66 : A294 - A294
  • [8] Impact of dose capping in insulin glargine/lixisenatide fixed-ratio combination trials in patients with type 2 diabetes
    Schmider, Wolfgang
    Belder, Rene
    Lee, Michelle
    Niemoeller, Elisabeth
    Souhami, Elisabeth
    Frias, Juan P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (06) : 1081 - 1089
  • [9] Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
    Handelsman, Yehuda
    Chovanes, Christina
    Dex, Terry
    Giorgino, Francesco
    Skolnik, Neil
    Souhami, Elisabeth
    Stager, William
    Niemoeller, Elisabeth
    Frias, Juan Pablo
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2019, 33 (03) : 236 - 242
  • [10] iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes
    Goldman, Jennifer
    Trujillo, Jennifer M.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (11) : 990 - 999
12345